Que es un Target Product Profile?

Documento que define las caracteristicas deseadas del producto final. Incluye: indicacion, poblacion, dosis, via, frecuencia, potencia objetivo, selectividad, PK, y requisitos de seguridad. Guia optimizacion y permite medir progreso.

Cuantos analogos se sintetizan tipicamente en LO?

Tipicamente 50-500 analogos durante toda la fase de lead optimization. En ciclos de 5-20 analogos cada 3-6 meses. El numero depende de complejidad del target y recursos disponibles.

Que es un backup compound?

Compuesto alternativo del mismo programa que se mantiene como opcion secundaria. Si el candidato principal falla en desarrollo, el backup puede avanzar. Tipicamente mismo mecanismo pero diferente estructura, para evitar mismo fallo.

Cuando se decide terminar un programa?

Cuando los datos indican que los objetivos del TPP no son alcanzables. Ejemplos: toxicidad insuperable, incapacidad de lograr potencia/ selectividad, PK inadecuada, costo de manufactura prohibitive. Decision dificil pero necesaria para asignar recursos eficientemente.

Optimizacion de Lead Peptidico

Categorías: Metodología de Investigación, Información General

La optimizacion de lead transforma un hit inicial en un candidato clinico con propiedades optimizadas.

Resumen Simplificado

El proceso optimiza potencia, selectividad, PK/PD, seguridad y manufacturabilidad iterativamente.

Definicion de hit y lead

Terminos tienen significado especifico. Hit. Initial activity. Confirmed reproducible. Dose-response. Structure verified. Not necessarily potent. May have liabilities. Lead. Optimized hit. Defined SAR. Acceptable potency. Drug-like properties. Clear path forward. Candidate. Fully optimized. Ready for clinical. IND-enabling studies done. Progression. Hit to lead. H2L. Lead optimization. LO. Candidate selection. Each stage. Different goals. Different studies. Increasing investment. Increasing certainty. Criteria for progression. Activity threshold. Selectivity window. PK profile. Safety margins. Synthesis feasibility. Patentability. Hit rate. Screening result. Many hits. Few leads. Fewer candidates. Definition is important. Common language. Stage-appropriate expectations.

Hit a lead

H2L es fase inicial. Hit confirmation. Resynthesize. Verify activity. Confirm structure. Counter-screening. Off-target effects. Selectivity baseline. Liability assessment. Stability. Initial PK. Preliminary. Synthesis optimization. Route development. Scalability check. Cost estimate. Early SAR. Alanine scan. Truncation. Key positions identified. Initial optimization. Improve potency. 10-fold if possible. Initial selectivity. Reduce obvious liabilities. Series selection. Multiple hits. Choose best series. Consider potential. Not just potency. Lead selection criteria. Potency target. uM to nM potential. Selectivity potential. PK potential. Safety profile. Patent space. Manufacturing potential. H2L defines series. Establishes potential. Go/no-go decision.

Optimizacion de lead

LO es fase intensiva. Goals. Improve potency. To clinical target. Optimize selectivity. Therapeutic window. Enhance PK. Appropriate half-life. Ensure safety. Toxicity profile. Enable manufacturing. Scalable synthesis. Design cycles. Hypothesis. Design analogs. Synthesize. Test. Analyze. Iterate. 3-6 months per cycle. Multiple cycles. 5-20 analogs per cycle. Total analogs. 50-500 typically. Multi-parameter optimization. Activity. Selectivity. PK. Safety. Balance needed. Decision tools. Target product profile. TPP. Define goals. Track progress. Gap analysis. Risk assessment. Decision points. Continue. Pivot. Terminate. Resource allocation. Team effort. Medicinal chemistry. Biology. DMPK. Formulation. Project management. Timeline. Budget. LO is resource intensive. Most expensive phase. Defines candidate quality.

Seleccion de candidato

Candidate selection es hito mayor. Criteria. Potency. Below target threshold. Selectivity. Sufficient window. PK. Desired profile. PD. Efficacy in models. Safety. No red flags. Manufacturing. Scalable route. Cost target. Formulation. Viable approach. Stability. Defined shelf-life. Patent. Filing planned. Competitive analysis. Differentiation. Risk assessment. Known liabilities. Mitigation plans. Comparators. Backup compounds. Data package. Complete. Documentation. CMC. Chemistry manufacturing control. Nonclinical. GLP studies. Clinical plan. Phase 1 design. Regulatory strategy. Pre-IND meeting. Timeline to clinic. Investment decision. Budget. Team assembled. Candidate selection is milestone. Major commitment. Transition to development.

Métricas de optimizacion

Metrics guian progreso. Potency metrics. IC50, EC50. Ki, Kd. Target engagement. Cellular activity. Selectivity indices. Fold vs off-targets. Therapeutic index. PK metrics. Half-life. Clearance. Volume. Bioavailability. Dosing projection. PD metrics. Duration of effect. Dose-response in vivo. Biomarker modulation. Efficacy models. Safety metrics. MTD. NOAEL. Safety margin. Therapeutic window. Chemistry metrics. Yield. Steps. Cost. Purity. Formulation metrics. Stability. Compatibility. Delivery. Lipinski-like rules. For peptides. Modified rules. Drug-like properties. Decision metrics. Go/no-go criteria. Stage gates. Tracking. Dashboard. Visual. Team alignment. Regular review. Course correction. Metrics are compass. Keep project on track.

Gestion de riesgos

Risk management es esencial. Risk types. Target risk. Biological hypothesis. Pharmacology risk. Translation to human. Safety risk. Toxicity unknowns. CMC risk. Manufacturing challenges. Regulatory risk. Approval uncertainty. Commercial risk. Market dynamics. Risk identification. Early. Transparent. All stakeholders. Risk assessment. Probability. Impact. Prioritize. Mitigation strategies. Backup compounds. Alternative approaches. Contingency plans. Kill criteria. When to stop. Courage to terminate. Portfolio view. Multiple projects. Balance risk. Stage-gate process. Formal reviews. Go/stop decisions. Continuation criteria. Risk tracking. Log. Update regularly. Learn from failures. Post-mortems. Knowledge capture. Risk management is not risk elimination. Is informed decision-making.

Hallazgos Clave

Hit es actividad inicial confirmada; lead es optimizado con path definido
H2L confirma estructura, establece SAR inicial y evalua liabilidades
LO optimiza potencia, selectividad, PK y seguridad iterativamente
La seleccion de candidato requiere datos completos y assessment de riesgo
Las metricas (IC50, half-life, therapeutic index) guian decisiones
Risk management identifica, evalua y mitiga riesgos del proyecto

Más artículos en Metodología de Investigación

Más artículos en Información General

Preguntas frecuentes

Que es un Target Product Profile?: Documento que define las caracteristicas deseadas del producto final. Incluye: indicacion, poblacion, dosis, via, frecuencia, potencia objetivo, selectividad, PK, y requisitos de seguridad. Guia optimizacion y permite medir progreso.
Cuantos analogos se sintetizan tipicamente en LO?: Tipicamente 50-500 analogos durante toda la fase de lead optimization. En ciclos de 5-20 analogos cada 3-6 meses. El numero depende de complejidad del target y recursos disponibles.
Que es un backup compound?: Compuesto alternativo del mismo programa que se mantiene como opcion secundaria. Si el candidato principal falla en desarrollo, el backup puede avanzar. Tipicamente mismo mecanismo pero diferente estructura, para evitar mismo fallo.
Cuando se decide terminar un programa?: Cuando los datos indican que los objetivos del TPP no son alcanzables. Ejemplos: toxicidad insuperable, incapacidad de lograr potencia/ selectividad, PK inadecuada, costo de manufactura prohibitive. Decision dificil pero necesaria para asignar recursos eficientemente.

Volver a la biblioteca de investigación